PLYMOUTH, Minn., Sept. 11 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq:
EVVV) today announced that Pat Spangler, chief financial officer, and Julie
Tracy, chief communications officer, are scheduled to present at the 2008
UBS Life Sciences Conference at 8:00 a.m. Eastern Time on Thursday,
September 25, 2008 at the Grand Hyatt New York located at 109 East 42nd
Street at Grand Central Terminal, New York, New York.
To access the webcast, go to the investors' section of the ev3 Web site
at http://ir.ev3.net and click on the Webcast icon. The Webcast will be
available for replay approximately one hour after the presentation is
complete.
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to developing
innovative, breakthrough and clinically proven technologies and solutions
for the treatment of lower extremity vascular and neurovascular diseases.
ev3's products are used by endovascular specialists to treat a wide range
of peripheral vascular and neurovascular diseases and disorders. The
company offers a comprehensive portfolio of treatment options, including
the primary interventional technologies used today -- peripheral
angioplasty balloons, stents, plaque excision systems, embolic protection
devices, liquid embolics, embolization coils, thrombectomy catheters and
occlusion balloons. More information about the company and its products can
be found at http://www.ev3.net.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.
and other countries.
|
